Practice Guideline
doi: 10.1016/j.remn.2009.11.003.
Epub 2009 Dec 5.
[Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society]
[Article in
Spanish]
Affiliations
- PMID: 19963305
- DOI: 10.1016/j.remn.2009.11.003
Item in Clipboard
Practice Guideline
[Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society]
[Article in
Spanish]
Rev Esp Med Nucl.
2010 Jan-Feb.
No abstract available
Similar articles
-
[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].Rev Esp Med Nucl. 2006 Jan-Feb;25(1):55-68; quiz 69-70.. doi: 10.1157/13083353. Rev Esp Med Nucl. 2006. PMID: 16540015 Review. Spanish. No abstract available.
-
[Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].Rev Esp Med Nucl. 2006 Jan-Feb;25(1):42-54. doi: 10.1157/13083351. Rev Esp Med Nucl. 2006. PMID: 16540013 Review. Spanish.
-
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Clinical Trial.
-
Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. doi: 10.1007/s002800100312. Cancer Chemother Pharmacol. 2001. PMID: 11587375 Review.
-
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).Semin Oncol Nurs. 2004 Feb;20(1 Suppl 1):8-13. doi: 10.1053/j.soncn.2004.02.008. Semin Oncol Nurs. 2004. PMID: 15160856 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
